Manufacturer: Sinoway
Pharmaceutical name: Recombinant Human Insulin Like Growth Factor-1 Des (1-3)
Pack: 1 vial (1 mg)
IGF-1 DES (often referred to as des(1-3)IGF-I in research) is a modified form of the naturally occurring IGF-1. The 70 amino acid variant of activated IGF-1 is crucial for normal growth and development in humans, acting through IGF-1 receptors to promote an anabolic effect that enhances muscle building, which is why it is significant in bodybuilding.
Low levels of IGF-1 are associated with stunted growth and several metabolic disorders. Various tissues in the body synthesize IGF-1, with the site of production influencing its functions. The liver produces the majority of IGF-1, which is then distributed to other tissues via the bloodstream, functioning as an endocrine hormone.
Significantly, IGF-1 serves as a key growth hormone that regulates the anabolic effects induced by growth hormone. Additionally, it possesses a growth-stimulating effect that operates independently of growth hormone, optimized when used in conjunction with it. IGF-1 DES has been specifically designed to exclude three amino acids at the end of natural IGF-1, enhancing its potency to about ten times greater than standard IGF-1. This increased potency arises from the fact that IGF-1 DES does not bind to IGF-binding proteins like IGF-1 does. Normally, IGF-binding proteins quickly hinder the growth-promoting functions of IGF-1, but they cannot attach to IGF-1 DES, allowing this peptide to freely facilitate muscle and bone growth, repair, and maintain smooth muscle health.
Research has demonstrated that IGF-1 DES can promote growth across various tissues in several animal studies. These studies also revealed that along with muscle gains, there was a reduction in excess body fat. In diabetic animals, the modified peptide exhibited beneficial effects throughout the digestive system and improved nutrient absorption. While there have been no clinical trials involving IGF-1 DES in humans, studies have indicated that the peptide is naturally present in the human brain, and research on brain cells has shown its potential to protect against brain injury and foster brain development.
IGF-1 DES has a brief half-life, deteriorating within 5 minutes of administration in humans. This short duration necessitates that IGF-1 DES 1 mg be administered intramuscularly. Doses of up to 100 mcg can be taken daily, divided between two to four muscle sites before workouts. A typical IGF-1 cycle should span four weeks and is best combined with an anabolic androgenic steroid for enhanced effectiveness.
Potential side effects of IGF-1 DES may include headaches and nausea, as the peptide can lead to a hypoglycemic state. Elevated levels of this hormone have also been linked to organ enlargement, so it is critical never to exceed the maximum recommended dose of 100 mcg per day.